Abstract 3901
Background
Efficacy data of treatment sequences in mRCC are rare. In the Czech Republic, data on efficacy and safety of all targeted therapies for mRCC are collected in the RENIS patient registry. Thus, RENIS provides data from the real-world clinical practice. The aim of this study was to compare outcomes of selected treatment sequences in mRCC while adjusting for differences in patient characteristics using inverse propensity score weighting method (IPWS).
Methods
Data of mRCC patients treated using most common treatment sequences were collected in RENIS between 06/2007 and 02/2018. Overall survival (OS) and progression free survival (PFS) were evaluated. Baseline characteristics were balanced using IPWS. The propensity score was evaluated with nominal logistic model to balance Eastern Cooperative Oncology Group (ECOG) performance status, time from diagnosis to first treatment, nephrectomy, Memorial Sloan-Kettering Cancer Center (MSKCC) score, and age. Median and confidence intervals (CI) were derived from IPWS weighted Kaplan-Meier curves that were compared using log-rank test.
Results
Overall, 745 patients in five treatment sequences were included and analysed. Differences in OS were significant (p < 0.001) with sunitinib→axitinib→everolimus and sunitinib→axitinib sequences associated with improved survival over other sequences. These differences could be also linked to time when these drugs were introduced. PFS did not differ between sunitinib and pazopanib used as first line treatments (p = 0.44) but the PFS in the second line differed significantly (p = 0.035) (Table). Table: Results of OS and PFS for examined sequences computed using inverse propensity score weighting. Sunitinib → Axitinib → Everolimus sequence should be assessed with caution due to immortal time bias.Table: 892P
| Parameter | Treatment sequence | n | Median | 95% CI for median | p | |
|---|---|---|---|---|---|---|
| Lower limit | Upper limit | |||||
| OS (months) | Sunitinib → Everolimus | 312 | 26.3 | 23.8 | 29.0 | <0.001 |
| Sunitinib → Axitinib | 154 | 47.6 | 31.3 | 50.5 | ||
| Sunitinib → Axitinib → Everolimus† | 114 | 46.0 | 44.7 | 50.9 | ||
| Pazopanib → Everolimus | 74 | 32.9 | 30.9 | 33.8 | ||
| Pazopanib → Sunitinib | 91 | 27.2 | 26.7 | 28.8 | ||
| PFS 1st line (months) | Sunitinib | 580 | 10.2 | 9.8 | 10.8 | 0.440 |
| Pazopanib | 165 | 9.2 | 8.5 | 10.0 | ||
| PFS 2nd line (months) | Sunitinib → Everolimus | 312 | 5.8 | 5.1 | 6.3 | 0.035 |
| Sunitinib → Axitinib | 268 | 6.4 | 6.0 | 7.1 | ||
| Pazopanib → Everolimus | 74 | 5.1 | 4.1 | 5.5 | ||
| Pazopanib → Sunitinib | 91 | 5.3 | 5.1 | 7.1 |
Conclusions
Improved outcomes were associated with sequences using second-line axitinib over those using second-line sunitinib or everolimus in a cohort of patients from a national registry.
Clinical trial identification
Legal entity responsible for the study
Jindrich Finek.
Funding
Value Outcomes.
Editorial Acknowledgement
Disclosure
J. Finek: Honoraria: Amgen, BMS, Roche, Bayer, Teva, MSD, Merck, Sanofi, Pierre Fabre. R. Demlova: Honoraria for lectures: Bayer. K. Kopeckova: Honoraria for lectures: Novartis; Travel grants: Pfizer, Bayer. T. Buchler: Honoraria for advisory boards and/or lectures: Novartis, Pfizer, Bayer, Roche. B. Melichar: Honoraria for advisory boards and/or lectures: Novartis, Pfizer, Glaxo Smith Kline, Roche, Bayer. A. Poprach: Honoraria for lectures: Novartis, Bristol-Myers Squibb, Roche, Bayer. T. Hrnciarova, T. Mlcoch, T. Dolezal: Employee of Value Outcomes. All other authors have declared no conflicts of interest.
Resources from the same session
1449 - Prognostic factors associated with pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy. The importance of Ki-67 and molecular subtype.
Presenter: Bernardo Rapoport
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4023 - The accuracy of sentinel lymph node biopsy following neoadjuvant chemotherapy in clinically node positive breast cancer patients: A single institution experience
Presenter: Narges Sistany Allahabadi
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4707 - Index BRCA1/2 testing under a multidisciplinary program
Presenter: Duarte Machado
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3393 - BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients
Presenter: Alex Friedlaender
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3175 - PALB2 germ-line mutations in Russian breast cancer patients: identification of recurrent alleles and analysis of phenotypic characteristics of the tumors
Presenter: Evgeny Imyanitov
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3027 - Landscape of germline mutations in hereditary breast and ovarian cancer (HBOC) patients in Russia revealed by target panel sequencing
Presenter: Elena Shagimardanova
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4963 - Lynch syndrome-associated hereditary mutations cause breast and ovarian cancer: results from Russian Heredetary Oncogenomics project
Presenter: Marat Gordiev
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2916 - Impact of deleterious germline BRCA mutations, addition of taxanes and use of adjuvant endocrine therapy (ET) on anti-müllerian hormone (AMH) levels in early breast cancer (EBC) patients treated by adjuvant chemotherapy (CT)
Presenter: Nathalie OLYMPIOS
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2400 - Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study
Presenter: Esther Pohl
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1345 - BRCA1/BRCA2 Predictive Genetic Testing in an Irish Population: A Missed Opportunity
Presenter: David O Reilly
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract